A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
For more information about the trial above please contact the study team:
Principal Investigator, John Kaczmar, at email@example.com, or please call +1 843-792-6691.
Study Coordinator, Carly Fecio, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina